Nebenwirkungen · Loqtorzi
LOQTORZI 240 mg concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 13
HOS-151554 · Präparat HOS-100567
Hepatotoxicity and immune-related hepatitis Immune-related hepatitis occurred in 2.0% (8/403) of patients receiving toripalimab in JUPITER-02 and JUPITER-06, including 2 (0.5%) Grade 4, 5 (1.2%) Grade 3, and 1 (0.2%) Grade 2 adverse reactions. The median time to onset of hepatitis was 4.0 months (range 0.7 to 22.7 months). The median duration was 0.6 months (range 0.4 to 3.2 months). Corticosteroids were administered to 7 of the 8 (87.5%) patients. Permanent discontinuation occurred in 5 (1.2%) and withholding of toripalimab in 2 (0.5%) patients. Immune-related hepatitis resolved in 87.5% (7/8) of these patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-04T15:02:00Z · SHA-256 eac1acbe0bafe6f5114659e9ef7795b23454eef58d31a89daab4ae4684038d34 · Passage 13bd23dea0f61ef794c441cfb626050019f01708980ca554274a94e9bda78d18 · Zeichen 14803–15423 im Abschnitt